

*Biopharmaceutical Fill-and-Finish:
Best Practices Study 2010*

Table of Contents

Presented by

HighTech Business Decisions

3150 Almaden Expressway, Suite 222, San Jose, CA 95118

Tel: (408) 978-1035 Fax: (408) 978-8925

www.hightechdecisions.com

September 2010

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

FORWARD AND ACKNOWLEDGMENTS

HighTech Business Decisions conducted the market research and wrote this report, *Biopharmaceutical Fill-and-Finish: Best Practices Study 2010*, to provide a comprehensive market analysis of the biopharmaceutical fill-and-finish contract manufacturing market worldwide. The research was specifically designed to understand current strategies for biomanufacturing, outsourcing practices and future plans, services needed and capacity requirements, decision criteria, current suppliers and collaborations, expenditures, pricing policies, and future strategies. The complete analysis, based on both user and supplier primary research, includes market size and growth, pricing, major players, user strategies and requirements, trends and technologies, and contractors' future plans for meeting biopharmaceutical fill-and-finish contract manufacturing requirements. In-depth data collected from both users and suppliers allowed for an objective and thorough analysis of the biopharmaceutical fill-and-finish contract manufacturing marketplace.

We thank the 41 respondents from pharmaceutical, biotechnology, and fill-and-finish contract manufacturing companies who took the time to share their insights, opinions, and future plans with us. We thank our sponsoring companies, who supported this project with their ideas, suggested topics, and funding for the first few months of this three-month project.

The following HighTech Business Decisions analysts and staff made important contributions to this research and report:

Analysts

Michael Biros, MBA	User and contractor interview
D.J. Cassell, Ph.D.	User and contractor interviews
Jennifer Hartigan, Ph.D.	User and contractor interviews and analysis
Lynne Sopchak, Ph.D.	User and contractor interviews

Staff

William Downey, MBA	Analysis and report
Cindy Liu, MBA	Project management, analysis and report
Dawn Miles, MBA	Project management, analysis and production

We hope that our clients obtain significant value from this report to help ensure the success of their future business.

Sincerely,

William Downey, MBA
President

September 2010

This report is Copyright protected by HighTech Business Decisions. All rights reserved. Printed and bound in the United States of America. Neither this report, nor parts of it, may be reproduced without written permission from HighTech Business Decisions.

HighTech Business Decisions has exercised due care in compiling this report, which is based on publicly available information as well as information submitted by individual companies. The company interview write-ups and profiles contained in this report are not intended to be a complete description of each company, but a paraphrased synopsis of interviews conducted with these companies from July to August 2010, combined with submitted material. The publishers have taken due care to ensure the accuracy of this information, but shall not be held liable for any consequential damages arising from the material in this report.

Copies of this report may be ordered from HighTech Business Decisions. To place an order, please call HighTech Business Decisions at (408) 978-1035, or visit www.hightechdecisions.com.

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

TABLE OF CONTENTS

Chapter 1:	EXECUTIVE SUMMARY	
	1.1 Introduction	1-1
	1.2 Market Overview	1-2
	1.2.1 Introduction	1-2
	1.2.2 Industry Drivers	1-2
	1.2.3 Market Size	1-4
	1.3 Summary of Customer Needs	1-5
	1.3.1 Products	1-5
	1.3.2 Outsourcing Strategies	1-7
	1.3.3 Outsourcing Budgets	1-8
	1.4 Summary of Fill-and-Finish Contractors' Capabilities	1-9
	1.4.1 Dosage Forms	1-9
	1.4.2 Capacity Increases	1-11
	1.4.3 Annual Revenue Ranges	1-11
	1.4.4 Contracting Business by Product Type	1-12
	1.5 Industry Trends and Observations	1-13
<hr/>		
Chapter 2:	METHODOLOGY, DEFINITIONS, AND ACRONYMS	
	2.1 Research Objectives	2-1
	2.2 Research Methodology	2-1
	2.3 Definition of Biopharmaceutical Manufacturing	2-3
	2.4 Acronyms	2-4
<hr/>		
Chapter 3:	FILL-AND-FINISH CONTRACT MANUFACTURING: MARKET OVERVIEW	
	3.1 Introduction	3-1
	3.2 Suppliers: The Fill-and-Finish Contract Manufacturers	3-2
	3.2.1 Types of Fill-and-Finish Contract Companies	3-2
	3.2.2 Fill-and-Finish Contract Companies	3-3
	3.2.3 Dosage Forms and Services	3-4
	3.2.4 Fill-and-Finish Contract Manufacturers' Capacities	3-6
	3.2.5 Revenues and Profit Margins	3-7

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

TABLE OF CONTENTS (continued)

Chapter 3:	3.3 The Customers: Pharmaceutical and Biotechnology Companies	3-8
	3.3.1 <i>Customers' Products</i>	3-8
	3.3.2 <i>Outsourced Fill-and-Finish by Dosage Form</i>	3-9
	3.3.3 <i>Customers' Future Outsourcing Expectations</i>	3-10
	3.3.4 <i>Outsourcing Needs</i>	3-11
	3.4 Market Capacity	3-13
	3.5 Market Size	3-15
	3.5.1 <i>Estimates of Market Size Based on Customer Spending</i>	3-15
	3.5.2 <i>Estimates of Market Size Based on Contractor Revenues</i>	3-16
	3.5.3 <i>Market Size by Dosage Form and Service Categories</i>	3-17
	3.6 Market Growth Forecasts	3-18
	3.7 Trends in the Fill-and-Finish Contract Manufacturing Market	3-19
	3.7.1 <i>Industry Innovations and Challenges</i>	3-19
	3.7.2 <i>Overall Industry Trends</i>	3-20
<hr/>		
Chapter 4:	PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CLIENT ANALYSIS	
	4.1 Introduction	4-1
	4.1.1 <i>Respondent Titles and Location</i>	4-1
	4.1.2 <i>Internal Manufacturing Sites</i>	4-2
	4.2 Manufacturing Demand	4-3
	4.2.1 <i>Manufacturing Needs</i>	4-3
	4.2.2 <i>Outsourced Products</i>	4-13
	4.2.3 <i>Clinical and Commercial Products</i>	4-16
	4.2.4 <i>Changes to Internal Filling Capacity</i>	4-19
	4.3 Manufacturing Technologies	4-22
	4.3.1 <i>Stabilization Technology</i>	4-22
	4.3.2 <i>Special Handling Requirements</i>	4-25
	4.3.3 <i>Avoiding Drug Substance Interaction with Fill Line</i>	4-29
	4.3.4 <i>Post-Filling Evaluation</i>	4-33
	4.3.5 <i>Use of Disposable Technology</i>	4-35
	4.3.6 <i>Challenges of Disposables Utilization</i>	4-40
	4.4 Outsourcing Strategies	4-45
	4.4.1 <i>Use of Manual Fill</i>	4-45
	4.4.2 <i>Current Outsourcing Strategy</i>	4-47
	4.4.3 <i>Future Outsourcing Strategy</i>	4-49

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

TABLE OF CONTENTS (continued)

Chapter 4:	4.5 Outsourcing Needs	4-52
	4.5.1 <i>Outsourced Services</i>	4-52
	4.5.2 <i>Additional Outsourcing Needs</i>	4-54
	4.6 Contractor Selection	4-57
	4.6.1 <i>Essential Characteristics Sought in a Contractor</i>	4-57
	4.6.2 <i>Competitive Advantage of a One-Stop-Shop</i>	4-65
	4.7 Contractor Pricing	4-71
	4.7.1 <i>Cost Models</i>	4-71
	4.7.2 <i>Technology Transfer Fees</i>	4-74
	4.7.3 <i>Reservation Fees</i>	4-77
	4.7.4 <i>Cancellation Fees</i>	4-80
	4.8 Outsourced Spending	4-83
	4.8.1 <i>Batch Pricing</i>	4-83
	4.8.2 <i>Outsourcing Budgets</i>	4-88
	4.8.3 <i>Outsourcing Budgets by Service Category</i>	4-90
	4.9 Contractor Relationships	4-94
	4.9.1 <i>Identifying Contract Partners</i>	4-94
	4.9.2 <i>Preferred Contractors</i>	4-97
	4.9.3 <i>Top Concerns of Contractors Meeting Expectations</i>	4-98
	4.9.4 <i>Opportunities for Improved Contractor-Client Relationship</i>	4-102
	4.10 Future Trends and Expectations	4-106
	4.10.1 <i>Future Fill-and-Finish Manufacturing Challenges and Bottlenecks</i>	4-106
	4.10.2 <i>New Products and Innovations Impacting Fill-and-Finish Manufacturing</i>	4-111
	4.10.3 <i>Future Trends in Biopharmaceutical Fill-and-Finish Contract Manufacturing</i>	4-113

Chapter 5: FILL-AND-FINISH CONTRACT MANUFACTURERS

5.1 Introduction	5-1
5.1.1 <i>Respondents' Titles and Experience</i>	5-1
5.1.2 <i>Company Locations</i>	5-2
5.1.3 <i>Regulatory Approval Status</i>	5-3
5.2 Capacity	5-3
5.2.1 <i>Dosage Forms</i>	5-3
5.2.2 <i>Current Capacity for Fill-and-Finish</i>	5-6
5.2.3 <i>Current Capacity for Lyophilization</i>	5-8
5.2.4 <i>Future Capacity Changes</i>	5-9

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

TABLE OF CONTENTS (continued)

Chapter 5:	5.3 Manufacturing Activity	5-11
	5.3.1 <i>Contracting Business by Product Type</i>	5-11
	5.3.2 <i>Current and Future Capacity Utilization</i>	5-13
	5.3.3 <i>Yield Recovery</i>	5-15
	5.3.4 <i>Production Work Schedule</i>	5-17
	5.4 Manufacturing Technologies	5-18
	5.4.1 <i>Current Use of Aseptic Technologies</i>	5-18
	5.4.2 <i>Verification of Accurate Filling</i>	5-19
	5.4.3 <i>Current Use of Disposables in Fill-and-Finish</i>	5-23
	5.4.4 <i>Concerns of Utilizing Disposables</i>	5-24
	5.4.5 <i>Technology Impact on Operations</i>	5-26
	5.5 Pricing	5-28
	5.5.1 <i>Price Structures for Fill-and-Finish</i>	5-28
	5.5.2 <i>Batch Pricing</i>	5-30
	5.5.3 <i>Service Pricing</i>	5-34
	5.5.4 <i>Contractors' Technology Transfer Fees</i>	5-36
	5.5.5 <i>Contractors' Reservation Fees</i>	5-39
	5.5.6 <i>Contractors' Cancellation Fees</i>	5-40
	5.5.7 <i>Gross Profit Margin</i>	5-43
	5.6 Customer Relationships	5-44
	5.6.1 <i>Contract Negotiation Roadblocks</i>	5-44
	5.6.2 <i>Strengths and Weaknesses of Contract Manufacturers</i>	5-47
	5.6.3 <i>Trade Shows</i>	5-50
	5.7 Fill-and-Finish Industry Revenues and Growth	5-50
	5.7.1 <i>Industry Growth</i>	5-50
	5.7.2 <i>Revenues</i>	5-52
	5.7.3 <i>Current and Expected Revenue Categories</i>	5-53
	5.7.4 <i>Revenues from Industry Segments</i>	5-55
	5.7.5 <i>Revenues from World Regions</i>	5-56
	5.8 Challenges for Fill-and-Finish Manufacturing	5-58
	5.8.1 <i>Low-Level Particulate Contaminants</i>	5-58
	5.8.2 <i>One-Stop-Shop CMO Model</i>	5-59
	5.9 Future Trends in Fill-and-Finish Manufacturing	5-62
	5.9.1 <i>Meeting Demand Surges</i>	5-62
	5.9.2 <i>Current and Future Aseptic Fill-and-Finish Facility Capital Costs</i>	5-64
	5.9.3 <i>Trends for the Future of Fill-and-Finish Contract Manufacturing</i>	5-67

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

TABLE OF CONTENTS (continued)

Appendix A: Write-Ups of Interviews with 29 Pharmaceutical and Biotechnology Company
BioManufacturing Directors Worldwide, Unnamed and Edited for Confidentiality

Appendix B: Directory of Biopharmaceutical Fill-and-Finish Contract Manufacturers

Appendix C: Interview Guide for Pharmaceutical and Biotechnology Company
Respondents

Appendix D: Interview Guide for Biopharmaceutical Fill-and-Finish Contract Manufacturers

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF TABLES

Chapter 1

1.2-1	Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Capacity Estimate in Units	1-3
1.3-1	Reasons for Outsourcing Fill-and-Finish Activities	1-7
1.4-1	Capacity Expansion by Contractor Type	1-11
1.5-1	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Manufacturing Trends	1-14
1.5-2	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Business Trends and Market Opportunities	1-14
1.5-3	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Concerns	1-15

Chapter 2

2.2-1	Market Research Steps	2-2
2.4-1	Acronyms	2-4

Chapter 3

3.2-1	Rating of Respondents' Fill-and-Finish Contract Manufacturers	3-3
3.2-2	Revenue by Service Category: 2009	3-5
3.2-3	Biopharmaceutical F&F Contract Manufacturing Industry Capacity Estimates in Units	3-7
3.3-1	Estimates of Needs for Outsourced Volumes for the Respondent Group	3-12
3.3-2	Estimates of Needs for Outsourced Volumes for the Worldwide Industry	3-13
3.4-1	Biopharmaceutical Fill-and-Finish Outsourced Manufacturing Capacity vs. Needs: Vials	3-14
3.4-2	Biopharmaceutical Fill-and-Finish Outsourced Manufacturing Capacity vs. Needs: Syringes	3-14
3.4-3	Biopharmaceutical Fill-and-Finish Outsourced Manufacturing Capacity vs. Needs: Other	3-14
3.5-1	Worldwide 2010 Market Size for Biopharmaceutical Fill-and-Finish Contract Manufacturing: Estimates Based on Customer Spending: US\$	3-16
3.5-2	Worldwide 2010 Market Size for Biopharmaceutical Fill-and-Finish Contract Manufacturing: Estimates Based on Contractors' Revenues: US\$	3-16
3.5-3	Market Size by Dosage Forms: US\$	3-17
3.5-4	Market Size by Service Category: US\$	3-17
3.7-1	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Manufacturing Trends	3-20
3.7-2	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Business Trends and Market Opportunities	3-21
3.7-3	Observations on Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry Trends: Concerns	3-21

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF TABLES (continued)

Chapter 4

4.1-1	Titles of Pharmaceutical and Biotechnology Company Respondents	4-1
4.1-2	Location of Internal Fill-and-Finish Manufacturing Sites	4-3
4.2-1	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Lyophilized)	4-4
4.2-2	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Not Lyophilized)	4-6
4.2-3	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Lyophilized)	4-9
4.2-4	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Not Lyophilized)	4-10
4.2-5	Respondents' Current and Expected Capacity Needs for Outsourced Products – Cartridges (Not Lyophilized)	4-11
4.2-6	Respondents' Current and Expected Capacity Needs for Outsourced Products – IV Bags (Not Lyophilized)	4-11
4.2-7	Respondents' Current and Expected Capacity Needs for Outsourced Products – Other (Not Lyophilized)	4-11
4.2-8	Number of Outsourced Products by Phase by Year	4-15
4.2-9	Outsourcing Percentage by Dosage Form	4-15
4.2-10	Number of Biopharmaceutical Products Filled in Vials	4-16
4.2-11	Number of Biopharmaceutical Products Filled in Syringes	4-16
4.2-12	Number of Biopharmaceutical Products Filled in IV Bags	4-17
4.2-13	Types of Respondents' Biopharmaceutical Products by Dosage Forms	4-19
4.3-1	Alternative Stabilization Technologies	4-23
4.3-2	Product Characteristics that Require Special Handling	4-26
4.3-3	Concerns About and Mitigation of Product Interaction with Fill Components	4-30
4.3-4	Post-Filling Evaluation Assessments	4-33
4.3-5	Disposables Used in Fill-and-Finish, Extent and Drivers of Use	4-37
4.3-6	Concerns About Use of Disposables in Fill-and-Finish Manufacturing	4-42
4.4-1	Circumstances for Use of Internal Manual Filling	4-46
4.4-2	Reasons for Outsourcing Fill-and-Finish Activities	4-47
4.5-1	Outsourcing of Fill-and-Finish Related Services	4-53
4.5-2	Number of Products Currently and Planned to Outsource by Service	4-53
4.5-3	Service or Technical Capabilities Desired in a Fill-and-Finish Contractor	4-54
4.6-1	Ranked Characteristics of a Good Service Level at Fill-and-Finish Contractor	4-58
4.6-2	Rationale for Number '1' Ranked Good Service Characteristic	4-61
4.7-1	Cost Model Used for Fill-and-Finish Services by Respondent Type	4-71
4.7-2	Cost Model Used for Fill-and-Finish Services by Product Phase	4-72
4.7-3	Average Technology Transfer Fees Paid by Dosage Form	4-75
4.8-1	Price Per-Batch by Dosage Form by Product Phase	4-84
4.8-2	Price Per-Unit by Dosage Form by Product Phase	4-86
4.8-3	Examples of Other Services and Material Charges	4-87
4.8-4	Fill-and-Finish Outsourcing Budget by Respondent Type: 2010, 2012, 2015	4-89
4.8-5	Simple Average: Percentage of F&F Outsourcing Budget by Service	4-91
4.8-6	Weighted Average: Percentage of F&F Outsourcing Budget by Service	4-93

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF TABLES (continued)

Chapter 4

4.9-1	Search Modes for Fill-and-Finish Contractors	4-95
4.9-2	Rating of Respondents' Fill-and-Finish Contract Manufacturers	4-97
4.9-3	Top Concerns of Fill-and-Finish Contractors Meeting Expectations	4-99
4.9-4	Opportunities for Improvements in Contractor-Client Relationship	4-103
4.10-1	Challenges Facing Fill-and-Finish Manufacturing	4-107
4.10-2	New Products and Innovations with an Impact on F&F Manufacturing	4-111
4.10-3	Future Trends in Fill-and-Finish Manufacturing	4-114

Chapter 5

5.1-1	Titles of Fill-and-Finish Contractor Respondents	5-1
5.1-2	Fill-and-Finish Contractors: Headquarter Locations	5-2
5.1-3	Regulatory Agency Approvals	5-3
5.2-1	Average Batch Size per Fill Line and Contractor	5-6
5.2-2	Fill Capacity by Batch Size at Respondents' Facilities in 2010	5-7
5.2-3	Lyophilizer Capacity by Shelf Space at Respondents' Facilities in 2010	5-8
5.2-4	Lyophilizer Capacity by Batch Size at Respondents' Facilities in 2010	5-9
5.2-5	Capacity Expansion by Contractor Type	5-10
5.2-6	Fill Line Expansion Plans	5-11
5.2-7	Lyophilizer Expansion Plans	5-11
5.3-1	Percent of Contracting Business by Product Type: 2009 and 2012	5-12
5.3-2	Capacity Utilization Rate: Fill Line	5-13
5.3-3	Capacity Utilization Rate: Lyophilization	5-15
5.3-4	Examples of Production Work Schedules	5-17
5.4-1	Technologies Used to Maintain Aseptic Fill-and-Finish Facilities	5-18
5.4-2	Technologies and Methods Used to Verify Fill Accuracy	5-20
5.4-3	Challenges of Filling Accurately	5-21
5.4-4	Disposables Used for Fill-and-Finish Manufacturing	5-23
5.4-5	Concerns About Using Disposables in Fill-and-Finish Manufacturing	5-24
5.4-6	Technologies that Impact Operations	5-26
5.5-1	Factors that Affect Pricing	5-29
5.5-2	Pricing Methods for Clinical and Commercial Phase	5-30
5.5-3	Batch Pricing by Dosage Form and Product Phase	5-31
5.5-4	Per-Unit Pricing by Dosage Form and Product Phase	5-33
5.5-5	Examples of Other Services and Material Charges	5-35
5.5-6	Average Per-Unit Pricing Based on Other Services and Materials	5-36
5.5-7	Types of Technology Transfer Fees	5-37
5.5-8	Contractors' Cancellation Fees: Average Percentages of Total Project Fee	5-41
5.5-9	Gross Profit Margin	5-43
5.6-1	Contract Negotiation Roadblocks	5-44
5.6-2	Contract Manufacturers' Strengths and Weaknesses	5-47
5.6-3	Top Trade Shows for Finding Quality Leads and Technical Information	5-50

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF TABLES (continued)

Chapter 5

5.7-1	Annual Growth Rates: Industry Estimate vs. Company Forecast	5-51
5.7-2	Annual Revenue Ranges in \$US for 2009 by Contractor Type	5-53
5.7-3	Revenue by Service Category: 2009	5-54
5.7-4	Revenue Change Expected by Service Category: 2009 to 2012	5-55
5.7-5	Customers by Average Percentage of Business	5-56
5.7-6	Average Percentage of Business from the World Regions	5-57
5.8-1	Concerns about Low-Level Particulates	5-58
5.8-2	Impact of a One-Stop-Shop Model	5-60
5.9-1	Meeting a Pandemic-Sized Surge in Demand	5-63
5.9-2	Future Trends in Fill-and-Finish Manufacturing	5-68

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF FIGURES

Chapter 1

1.2-A	Size of Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Industry in US\$B	1-5
1.3-A	Respondents' 102 Biopharmaceutical Products by Phase	1-6
1.3-B	Number of Products Outsourced by Dosage Form: 2010, 2012, 2015	1-6
1.3-C	Fill-and-Finish Outsourcing Strategy: Future Changes	1-8
1.3-D	Simple Average Percentages of Expected Overall Outsourced Budget	1-9
1.4-A	Dosage Forms Produced by Number of Contractor Respondents	1-10
1.4-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	1-10
1.4-C	Annual Revenue Ranges in \$US for 2009 by Number of Contractors	1-12
1.4-D	Percent of Contracting Business by Product Type: 2009 and 2012	1-13

Chapter 3

3.2-A	Dosage Forms Produced by Number of Contractor Respondents	3-4
3.2-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	3-5
3.3-A	Respondents' 102 Biopharmaceutical Products by Phase	3-8
3.3-B	Percent of Products Outsourced: 2010	3-9
3.3-C	Simple Average Percentages of Expected Overall Outsourcing Budget	3-10
3.3-D	Number of Products Outsourced by Dosage Form: 2010, 2012, 2015	3-11
3.6-A	Size of the Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Market in US\$B	3-19

Chapter 4

4.1-A	Internal Fill-and-Finish Manufacturing Capability	4-2
4.2-A	Summation of Outsourced Units Required – Vials	4-12
4.2-B	Summation of Outsourced Units Required – Syringes	4-13
4.2-C	Percentage of Products Outsourced – Vials: 2010	4-14
4.2-D	Percentage of Products Outsourced – Syringes: 2010	4-14
4.2-E	Number of Respondents' Products Produced by Dosage Form and Phase	4-17
4.2-F	Respondents' 102 Biopharmaceutical Products by Phase	4-18
4.2-G	Respondents' 102 Biopharmaceutical Products by Company Type	4-18
4.2-H	Changes to Internal Filling Capacity	4-20
4.3-A	Interest in Stabilization Technology Other Than Lyophilization	4-23
4.3-B	Need for Special Product Handling Methods During F&F Manufacturing	4-26
4.3-C	Concern of Drug Substance Interaction with Filling Components	4-30
4.3-D	Use of Disposable Components in Fill-and-Finish Manufacturing	4-36
4.3-E	Different Use of Disposables by Respondent Type	4-38
4.3-F	Concerns About Disposable Use in Fill-and-Finish Manufacturing	4-41
4.4-A	Internal Manual Filling of Drug Substance	4-45
4.4-B	Fill-and-Finish Outsourcing Strategy: Future Changes	4-49
4.4-C	Fill-and-Finish Outsourcing Strategy Changes	4-50

Biopharmaceutical Fill-and-Finish: Best Practices Study 2010

LIST OF FIGURES (continued)

Chapter 4

4.6-A	Number '1' Ranked Good Service Characteristics	4-58
4.6-B	Most Important Good Service Characteristics by Weighted Average	4-59
4.6-C	Distribution of Weighted Ranks by Respondent Type	4-60
4.6-D	Competitive Advantage of a One-Stop-Shop CMO	4-65
4.6-E	Distribution of Opinion About One-Stop-Shop CMOs by Respondent Type	4-66
4.6-F	Advantages and Disadvantages of a One-Stop-Shop CMO	4-67
4.7-A	Average Technology Transfer Fees Paid by Respondent Type	4-75
4.7-B	Payment of Reservation Fees	4-78
4.7-C	When Cancellation Charges are First Expected to be Incurred	4-80
4.7-D	Cancellation Fees: Average Percentages of the Total Contract Fee	4-81
4.8-A	Average Per-Batch Price by Dosage Form and Clinical Phase	4-85
4.8-B	Average Per-Unit Price by Dosage Form and Clinical Phase	4-87
4.8-C	Average Fill-and-Finish Outsourcing Budgets by Respondent Type	4-90
4.8-D	Simple Average: Percentage of F&F Outsourcing Budget by Service: 2010	4-92
4.8-E	Weighted Average: Percentage of F&F Outsourcing Budget by Service	4-94

Chapter 5

5.1-A	Number of Years Fill-and-Finish Services Offered	5-2
5.2-A	Dosage Forms Produced by Number of Contractors Respondents	5-4
5.2-B	Percent of Fill Lines Available among Contractor Respondents for Various Dosage Forms	5-4
5.2-C	Comparison of Percent of Dosage Forms Produced by Contractor Type	5-5
5.2-D	Capacity Expansion Plans	5-10
5.3-A	Percent of Contracting Business by Product Type: 2009 and 2012	5-13
5.3-B	Fill Line Capacity Utilization Rates for 2010 and 2012	5-14
5.3-C	Lyophilization Capacity Utilization Rates for 2010 and 2012	5-15
5.3-D	Average Yield Recovery Percentage Distribution	5-16
5.4-A	Technologies Used to Verify Fill Accuracy by Contractor Type	5-20
5.4-B	Challenges of Filling Accurately by Contractor Type	5-22
5.5-A	Pricing Methods for Fill-and-Finish and Lyophilization Services	5-29
5.5-B	Average Batch Pricing by Dosage Form and Product Phase	5-32
5.5-C	Average Per-Unit Pricing by Dosage Form and Product Phase	5-34
5.5-D	Technology Transfer Fee Charged	5-37
5.5-E	Reservation Fee Charged	5-39
5.5-F	When Cancellation Fees Are First Charged	5-41
5.5-G	Targeted and Achieved Gross Profit Margins	5-43
5.6-A	Negotiation Roadblocks by Contractor Type	5-45
5.7-A	Annual Growth Rates: Industry Estimate vs. Company Forecast	5-51
5.7-B	Annual Revenue Ranges in \$US for 2009 by Number of Contractors	5-53
5.7-C	Service Revenue by Contractor Type: 2009	5-54
5.7-D	Revenue Contribution from Customer Groups by Contractor Type	5-56
5.7-E	Percentage of Business from the World Regions by Contractor Type	5-57
5.8-A	Impact of a One-Stop-Shop on the Biopharmaceutical Fill-and-Finish Contracting Industry	5-60
5.9-A	Capital Costs for an Aseptic Fill-and-Finish Facility	5-65
5.9-B	Future Trends Identified by Contractor Type	5-69